血管质量倡议试点:EVAR 医院成本与报销差异研究
结果显示总成本在中心间差异达2–3倍,除无并发症标准EVAR外医保报销均低于总成本,仅9%有并发症病例被编码为高报销DRG 237。
要点
- 合并VQI临床数据与账单数据可实现EVAR成本的精准分组比较。
- 中心间EVAR总成本差异达2–3倍,植入物成本差异亦超预期。
- 多数EVAR病例医保报销低于总成本,有并发症者尤为明显。
核心结论
- VQI临床数据可识别可比临床组,比单纯DRG编码更精确地比较EVAR成本。
- 总成本超过医保报销,尤其在有并发症患者中,但各中心间存在差异。
- 将记录EVAR病例复杂度的VQI数据元素纳入账单数据,可能帮助中心使DRG报销与总成本更好匹配。
研究设计与样本
- 按标准或复杂(含股-股旁路或额外动脉治疗)及无或有并发症分为四组进行比较。
- 由MedAssets公司利用成本收费比计算总医院成本及成本类别,并与DRG 237和238编码比较。
- 利用VQI临床数据建立预测DRG 237编码的多变量模型。
主要发现
- 782例EVAR中56%为标准术式,15%有并发症,中心间差异大。
- 平均总成本从无并发症标准EVAR的31,100美元到有并发症复杂EVAR的47,400美元,中心间差异达2–3倍。
- 无并发症标准EVAR的植入物成本在各中心间从8,100美元到28,200美元不等。
- 除无并发症标准EVAR外,平均Medicare报销低于总成本。
- VQI中有并发症的病例仅9%被报告为高报销的DRG 237(中心范围0%–21%),医院DRG 237编码与预期率相比存在显著差异。
临床怎么用
- 可借鉴VQI与账单数据合并方法,按临床复杂度分组评估EVAR真实成本与报销差距。
- 关注有并发症EVAR的报销不足,并核查本院DRG 237编码是否充分反映病例复杂度。
- 对植入物成本进行中心间对标,识别可优化的成本差异。
局限性
- 仅纳入2014年择期肾下EVAR,未涉及急诊或其他主动脉手术。
- 成本计算依赖成本收费比,可能受各中心收费结构影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Comparing costs between centers is difficult because of the heterogeneity of vascular procedures contained in broad diagnosis-related group (DRG) billing categories. The purpose of this pilot project was to develop a mechanism to merge Vascular Quality Initiative (VQI) clinical data with hospital billing data to allow more accurate cost and reimbursement comparison for endovascular aneurysm repair (EVAR) procedures across centers. METHODS: Eighteen VQI centers volunteered to submit UB04 billing data for 782 primary, elective infrarenal EVAR procedures performed by 108 surgeons in 2014. Procedures were categorized as standard or complex (with femoral-femoral bypass or additional arterial treatment) and without or with complications (arterial injury or embolectomy; bowel or leg ischemia; wound infection; reoperation; or cardiac, pulmonary, or renal complications), yielding four clinical groups for comparison. MedAssets, Inc, using cost to charge ratios, calculated total hospital costs and cost categories. Cost variation analyzed across centers was compared with DRG 237 (with major complication or comorbidity) and 238 (without major complication or comorbidity) coding. A multivariable model to predict DRG 237 coding was developed using VQI clinical data. RESULTS: Of the 782 EVAR procedures, 56% were standard and 15% had complications, with wide variation between centers. Mean total costs ranged from $31,100 for standard EVAR without complications to $47,400 for complex EVAR with complications and varied twofold to threefold among centers. Implant costs for standard EVAR without complications varied from $8100 to $28,200 across centers. Average Medicare reimbursement was less than total cost except for standard EVAR without complications. Only 9% of all procedures with complications in the VQI were reported in the higher reimbursed DRG 237 category (center range, 0%-21%). There was significant variation in hospitals' coding of DRG 237 compared with their expected rates. VQI clinical data accurately predict current DRG coding (C statistic, 0.87). CONCLUSIONS: VQI data allow a more precise EVAR cost comparison by identifying comparable clinical groups compared with DRG-based calculations. Total costs exceeded Medicare reimbursement, especially for patients with complications, although this varied by center. Implant costs also varied more than expected between centers for comparable cases. Incorporation of VQI data elements documenting EVAR case complexity into billing data may allow centers to better align respective DRG reimbursement to total costs.
引用
- Lemmon GW, Neal D, DeMartino RR, et al. Variation in hospital costs and reimbursement for endovascular aneurysm repair: A Vascular Quality Initiative pilot project. J Vasc Surg. 2017. PMID: 28502551. doi:10.1016/j.jvs.2017.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。